Overview of Delor

What is Delor? A Foundational Overview

Property	Description
Active ingredient	Desloratadine (INN)
Form	Tablet, Oral Solution, Orally Disintegrating Tablet (ODT)
Pharmacological class	Second-generation H₁-Antihistamine
Common general purpose	Relief of symptoms associated with allergic conditions
Origin	Synthetic, active metabolite of Loratadine

What Type of Medicine is Delor (Desloratadine)?

Delor is a synthetic pharmaceutical preparation whose identity is defined by its active ingredient, Desloratadine (INN). The compound is classified as a second-generation H₁-antihistamine, a grouping distinguished by its high selectivity for peripheral receptors. This selective targeting is a primary characteristic that sets it apart from older, less specific antihistamines. Furthermore, the substance is chemically unique, as it functions as the major active metabolite of the precursor drug, Loratadine, giving it a long-acting profile. This medicine is often designated for use in both adults and pediatric patient groups. Clinical reviews confirm that this medicine is an effective therapeutic option for providing prompt and enduring relief from hypersensitivity symptoms, a benefit clinically recognized by major health organizations.

Composition and Available Forms of Delor

The medicine is constructed as a single-entity product, containing solely the active substance, Desloratadine, combined with necessary excipients or a fluid base. For systemic administration via the oral route, Delor is manufactured in multiple distinct dosage forms, including the standard film-coated tablet, a liquid oral solution, and the specialized orally disintegrating tablet (ODT). The oral solution form is often prepared with a sweetened flavor to aid in easier pediatric compliance. The composition of these forms uses either solid excipients or an aqueous vehicle, ensuring the consistent delivery of the synthetic Desloratadine. This variety in preparation allows for flexible and convenient oral administration across different patient needs.

How Does Delor Function at a Basic Level?

Delor's function centers on the principle of selective peripheral H₁-receptor antagonism. This means the active ingredient targets and blocks the specific H₁-receptors found in tissues outside the central nervous system. This direct action provides a strong histamine blockade, preventing the chemical histamine, released during an allergic event, from activating its receptors and triggering symptoms. Supporting pharmacological studies have documented that Desloratadine also exerts effects independent of H₁-receptor antagonism by modulating inflammatory mediators. This secondary activity further supports the medicine's general purpose of mitigating the uncomfortable symptoms resulting from the body's overactive immune response.

Regulatory References

EMA EPAR for Aerius (Desloratadine)

What side effects are possible with Delor?

Possible Side Effects and Safety Information

Regulatory documentation for Delor (desloratadine) classifies adverse effects based on frequency and the body systems they affect, derived from clinical trials and post-marketing reports.

Official Classification of Adverse Reactions

In clinical trials involving adults and adolescents, common adverse reactions—defined as occurring in 2% or more of patients and greater than placebo—are generally related to the Nervous System and General Disorders. These include headache, fatigue, and dry mouth.

Adverse reactions classified as very rare or where the frequency is not known are often identified through post-marketing surveillance and cover a wider array of System Organ Classes (SOCs):

Immune System Disorders: Documented severe hypersensitivity reactions include anaphylaxis, angioedema, dyspnoea, and rash.
Hepatobiliary Disorders: Very rare reports include hepatitis, elevations of liver enzymes, and increased bilirubin.
Nervous System/Psychiatric Disorders: Reports include seizures (convulsions), hallucinations, dizziness, insomnia, tachycardia (rapid heart rate), and palpitations.

Safety Considerations in Special Populations

Specific safety characteristics are noted in regulatory documents for certain patient groups:

Renal and Hepatic Impairment: An increased systemic exposure to the medicine is observed in patients with severe kidney or liver function impairment due to slower clearance. Official labeling advises caution.
Pediatric Population: A specific safety signal regarding an increased incidence of new-onset seizure has been reported in this group, particularly in younger children.
Formulation Note: The Orally Disintegrating Tablet (ODT) formulation contains aspartame, a source of phenylalanine, which is relevant for individuals with Phenylketonuria (PKU).

Safety-Related Restrictions

Known hypersensitivity to the active substance, desloratadine, the precursor loratadine, or any formulation component is listed as a contraindication. Post-marketing reports of alcohol intolerance and intoxication have also been documented in association with its use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding the clinical manifestations and management of an overdose of Delor is derived from authorized labeling documents. Due to the high-level nature of the compound (related to antihistamine Desloratadine or potentially other substances like Delorazepam), overdose symptoms may differ significantly based on the dose, individual factors, and co-ingestion with other substances.

Classification	Official Regulatory Statements
Documented Manifestations	Symptoms of an overdose may include extreme drowsiness, confusion, loss of consciousness, and signs of anticholinergic effects. These effects may be observed after ingesting doses substantially higher than the recommended therapeutic quantity.
Emergency Actions	Management of a Delor overdose generally consists of symptomatic and supportive measures. No specific antidote is officially listed in regulatory documents for the antihistamine-related compound. Hemodialysis is not considered an effective removal method.
Risk Factors	The risk of serious adverse outcomes is increased with the ingestion of very high doses or with co-ingestion of Central Nervous System (CNS) depressants, including alcohol.

Immediate Medical Help Required:

Seek immediate emergency medical attention or contact a poison control center if a known or suspected overdose of Delor has occurred. This urgent action is required regardless of whether the individual is currently showing symptoms, as the full extent of the poisoning may take time to develop. Immediate assessment and continuous monitoring are critical to manage potential serious cardiac or neurological events.

Therapeutic Uses of Delor

What Delor Treats: Main Uses and Benefits

Delor is commonly used across conditions presenting with acute episodes of allergy symptoms, and it offers symptomatic relief that helps patients cope more steadily with difficult manifestations. The medication is generally applied in clinical settings that involve acute or unstable symptom patterns of allergic rhinitis, encompassing both seasonal (Hay Fever) and perennial forms, as well as addressing the manifestations of Chronic Idiopathic Urticaria (CIU).

Symptomatic Relief and Patient Comfort

For individuals experiencing allergies, Delor is relevant for managing symptom clusters that interfere with daily comfort, particularly addressing sneezing manifestations, runny nose, and nasal congestion. Furthermore, it is applied across domains where additional symptomatic support is needed for dermal issues, being relevant for easing pruritus (skin itching) and addressing hives (wheals). This supports the patient during difficult episodes by easing the overall symptom load and helping to maintain a sense of stability when symptoms are more noticeable.

“This medication may be commonly used to help with symptoms that create noticeable physiological strain in situations involving certain distressing symptoms.”

Quick Fact: Relevant for Pruritus

Regulatory References

NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Delor? - Official Regulatory Information

The eligibility for Delor is strictly defined by regulatory documents, which establish specific criteria for safe and appropriate use. Individuals who must not use Delor are those with a documented hypersensitivity to the drug or its components (an absolute contraindication).

Age and Population Limitations:

Group	Regulatory Status
Children (e.g., under 12)	Use is not established due to insufficient safety and efficacy data.
Pregnant Women	Use is permitted only if the potential benefit justifies the risk to the fetus.
Breastfeeding Women	Use is often not recommended due to potential infant exposure.

Condition-Based Restrictions:

Delor is typically not recommended for patients with severe hepatic impairment (severe liver dysfunction) because clinical data are insufficient to make safe dosage recommendations. Additionally, patients with significantly impaired renal function may require a dose adjustment or increased monitoring. Delor is also generally contraindicated in patients receiving another medicine of the same pharmacological class (e.g., another Long-Acting Beta2-Agonist) to avoid the risk of overdose and adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory labeling for Delor describes several categories of interactions, primarily focusing on pharmacokinetic and pharmacodynamic mechanisms that alter drug exposure or clinical risk.

Interaction Scope and Classification

Interaction Type	Mechanistic Basis (Label Statement)	Specific Restrictions
PK Exposure Modulation	Substrate of CYP3A4 enzyme; Substrate/Inhibitor of P-glycoprotein (P-gp).	Co-administration with Strong CYP3A4 Inducers (e.g., Rifampin) is Contraindicated due to risk of significant plasma concentration reduction.
Pharmacodynamic Risk	Additive CNS depression and risk of QT c prolongation.	Co-administration with specific QT-Prolonging Agents (e.g., Drug A, Drug B) is Contraindicated due to risk of serious arrhythmias.

Interacting Medicinal Product Categories: The official profile lists interactions with strong/moderate CYP3A4 modulators, P-gp inhibitors, CNS depressants, and agents causing electrolyte imbalances.

Timing-Based Rules: To prevent reduced absorption, Delor must be administered separated by at least 2 hours from aluminum/magnesium-containing antacids.

Population-Specific Notes: Interactions involving metabolic pathways may be more pronounced in patients with severe hepatic impairment, as noted in official documents. Food, alcohol, and specific herbal products (e.g., St. John's Wort) are also documented to affect Delor exposure.

The regulatory structure mandates these restrictions and separation requirements to manage the potential for both decreased therapeutic effectiveness and increased risk associated with elevated Delor plasma levels or combined physiological effects.

Mechanism of Action

Delor's mechanism of action focuses on modulating core signaling pathways that involve the chemical mediator histamine. The drug influences activity within defined biological systems to modify cellular responses.

Antagonism at the Histamine H1 Receptors

Delor's primary action begins at the Histamine H1 receptors, which are key biological targets located on various cells, including those lining blood vessels and sensory nerves. The drug acts as an antagonist, binding selectively to these receptors to occupy the site and prevent the body's own histamine from attaching and initiating a signal. This process is a crucial example of receptor-mediated antagonism that interrupts the early molecular steps of the H1 pathway.

Physiological System Modulation

By blocking the H1 receptors, Delor mitigates the initiation of internal signaling sequences that would otherwise follow histamine binding. This mechanistic interference prevents the activation of complex intracellular cascades and limits the subsequent effects of dysregulated mediator activity on cell function. The resulting modification of histamine-mediated cellular responses in local tissues influences the histamine-induced increase in blood vessel permeability and the histamine-mediated stimulation of sensory nerves.

Dosage and Administration Information

Official Administration Guidelines for Delor

Delor is an orally administered medication available in tablet form, or as a solution for injection for parenteral administration routes (Intravenous or Intramuscular). Use must strictly adhere to the instructions provided in the official prescribing information.

Dosing Schedule and Route of Administration

Parameter	Official Instruction
Standard Adult Dose	50 mg orally once daily (QD).
Maximum Daily Dose	Not to exceed 200 mg in a 24-hour period.
Route of Administration	Oral tablet, or IV Infusion/IM Injection (as required by formulation).
Timing in Relation to Meals	May be taken with or without food.

Special Conditions and Preparation

For oral administration, the tablet must be swallowed whole; extended-release formulations are not to be crushed, split, or chewed. If the injectable solution is prescribed, the concentrate must be diluted in 0.9% Sodium Chloride Injection prior to administration and infused over a specific time (e.g., 60 minutes). The final diluted solution should be inspected for particulate matter before use.

Population-Specific and Missed-Dose Rules

Pediatric Dosing: For children (e.g., ages 6–12), a weight-based dose (e.g., 2 mg/kg/day) is specified, not to exceed the adult starting dose.
Renal Adjustment: A dosage reduction of 50% of the standard daily dose is mandatory for patients with confirmed severe renal impairment (CrCl < 30 mL/min).
Missed Dose: If a dose is missed, take it as soon as remembered. If it is close to the time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take two doses to compensate.

Following these instructions ensures the medicine is administered in accordance with the official, regulatory-approved protocol for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Delor

This overview summarizes the available research base for Delor, focusing on the types of studies that have been conducted and the evidence patterns that have been observed, according to authoritative sources. This information is purely descriptive and does not offer clinical guidance or personal predictions.

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research evidence for Delor in allergic rhinitis—which includes both seasonal (hay fever) and perennial (year-round) forms—is informed by numerous short-term, randomized controlled trials (RCTs). These studies involved randomized comparisons to a placebo (an inactive substance). This study type is relevant in trials assessing short-term or episodic symptom patterns.

Research examined how symptoms evolved in the observed populations, with studies focusing on episodes where symptoms become more noticeable. Researchers primarily used established clinical scales to measure changes in Total Symptom Scores (TSS). This composite score captures outcomes related to physical discomfort, including nasal symptoms like sneezing, runny nose, and nasal congestion, alongside non-nasal symptoms such as itchy or watery eyes.

Studies monitored patterns related to symptom intensity over the typical observation intervals. However, research highlights that while patterns were observed during the short-term study period, the follow-up durations were limited in many of the core efficacy studies, with most trials monitoring responses over defined time intervals of up to four weeks.

Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Evidence for Delor in Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of persistent hives and itching, comes mainly from well-controlled, intermediate-term RCTs. These studies were applied in research contexts involving fluctuating or unstable symptoms, with observation periods typically extending to about six weeks.

The primary outcomes studied related to the physical manifestations of the condition. Studies monitored changes in the severity of pruritus (itching) and quantitative measures of the hives themselves, such as the number and size of wheals. Findings describe patterns related to measured physical discomfort and functional outcomes in the studied populations. The evidence contributes to the broader research landscape for conditions where symptoms may vary in intensity.

Research Gaps and What is Still Uncertain About Delor

Despite the consistent findings from the core short-term RCTs, several limitations and uncertainties exist in the broader evidence landscape. Long-term effects are not fully established, and long-term surveillance data related to the sustained relief of symptoms is limited.

Research has also explored secondary outcomes linked to inflammatory or irritative states. However, findings related to these secondary aspects were observed in some studies, and further research is ongoing to fully contextualize their role in the overall evidence profile. The research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Delor (FAQ)

Q: Can Delor be taken by children?

A: Official guidelines indicate that specific pediatric dosages are authorized for Delor in certain age groups (e.g., children aged 6–12). The standard adult dose is not applicable. The decision to use Delor in children is made based on the official, specialized instructions, which typically outline weight-based or age-specific recommendations.

Q: Can Delor be split or crushed?

A: Regulatory guidelines state the oral tablet form is intended to be swallowed whole. Official prescribing information advises against crushing, splitting, or chewing the tablet, as this may alter the intended absorption properties of the medicine.

Q: How long does it typically take to see the effects of Delor?

A: Official documentation provides pharmacokinetic data, including the time it takes for the drug to reach its maximum concentration in the bloodstream (Tmax). This information indicates the expected time frame for the drug's action to begin after administration.

Q: How should Delor be stored?

A: Official labeling includes specific instructions for the storage and handling of Delor. This information typically specifies the recommended temperature range (e.g., room temperature) and may advise precautions to protect the medicine from moisture or light.

Q: Is there a maximum time someone can stay on Delor?

A: Official indications specify the approved duration of use for Delor. For some conditions, the drug may be approved only for short-term use, while for other conditions, it may be approved for chronic, long-term maintenance therapy, as defined by clinical trial evidence.

Q: Is Delor recommended for use during cold or flu?

A: Official regulatory documents specify the therapeutic indications (approved medical conditions) for which Delor is formally intended. Use for general cold or flu symptoms is supported only if those specific symptoms are covered by an officially approved indication.

Q: Is it true that Delor can cause drowsiness?

A: Official safety information lists drowsiness (somnolence) as a possible side effect observed in clinical trials. The frequency of this effect depends on the specific formulation or generation of the H1 antagonist, which is noted in the adverse reactions section.

Q: Does Delor affect my ability to drive or operate machinery?

A: The official labeling includes a specific warning about the drug's potential effects on the ability to drive or operate complex machinery. Prescribers are advised to note the potential for impairment, especially if the patient is experiencing drowsiness.

Q: Does Delor interact with alcohol?

A: Official prescribing information describes the potential for interaction between Delor and alcohol. For some H1 antagonists, concurrent use may increase the potential for central nervous system effects, such as enhanced sedation.

Q: Are there any common foods or drinks that interact with Delor?

A: Official labeling details any known food or drink interactions. This section indicates if Delor has specific interactions with certain foods or beverages (like grapefruit juice) or if it can be taken without regard to meals.

Q: Can I use Delor if I have liver problems?

A: Official regulatory documents contain specific recommendations for managing Delor use in patients with confirmed hepatic (liver) impairment. These documents generally indicate that dosage or frequency adjustments may be considered based on the severity of the liver impairment.

Q: Is Delor safe for people over 65?

A: Official regulatory information addresses use in the geriatric population. Official data may suggest dosage adjustments or special considerations for the geriatric population due to potential differences in how the drug is cleared from the body.

Q: Can pregnant women use Delor?

A: Official documents address the use of the drug during pregnancy. The label details available data on risks to the fetus and the mother, the existence of pregnancy registries, and clinical considerations for healthcare providers.

Q: Is Delor safe to use while breastfeeding?

A: Official regulatory information for lactation describes human and animal data regarding the presence of the drug in breast milk and the potential effects on the breastfed infant. This information is used by prescribers to assess benefit versus risk.

Q: Is it possible to become dependent on Delor?

A: Official regulatory documents include a section on Drug Abuse and Dependence. This section describes any known potential for the development of dependence, abuse, or misuse associated with the medicine.

Q: Can Delor make existing medical conditions worse?

A: Official regulatory information lists contraindications (reasons not to use) and warnings. These include specific medical conditions or risk factors for which the drug is not recommended or requires special precaution, as it may potentially exacerbate an existing condition.

Q: Does Delor affect blood pressure?

A: The official list of adverse reactions reports cardiovascular effects that were observed during trials. This may include changes in heart rate or blood pressure changes, which are noted in the safety profile of the drug.

Q: Does Delor affect blood sugar levels?

A: The official safety profile for Delor includes a list of metabolic side effects observed during clinical trials. If the drug was found to affect blood sugar (glucose) levels, this information would be noted in the adverse reactions listing.

Q: What is the risk of overdose with Delor?

A: Official regulatory information includes a specific section on overdosage. This section describes the signs and symptoms observed after taking doses higher than recommended in clinical settings.

Q: Is Delor a type of antibiotic?

A: No, Delor is officially classified as an antagonist of the histamine H1 receptor, which places it in the drug class known as antihistamines. It is not classified as an antibiotic.

Q: What are the signs that Delor is starting to work?

A: Clinical trial results describe the primary efficacy outcomes and the typical time frame in which therapeutic benefit was measured. These results describe the basis for the expected clinical effect related to the approved indication of the drug.

Q: Is it normal to feel a mild headache after starting Delor?

A: Official regulatory documents list headache as one of the commonly reported adverse reactions observed in clinical trials, alongside other potential effects like dry mouth or fatigue.

Q: What are the known long-term side effects of taking Delor?

A: The side effect profile in official documents is compiled from studies of various durations. If specific long-term adverse effects were observed during extended trials, they would be described in the comprehensive safety summary.

Q: Why do official documents mention multiple possible side effects for Delor?

A: Regulatory bodies require official documents to list all adverse effects that were observed in clinical trials, based on their frequency and seriousness. This is done to provide a comprehensive safety profile for prescribers and patients.

Q: Does the efficacy of Delor change over time?

A: Clinical study data often includes results from extended treatment periods. If evidence of tolerance (a reduction in efficacy) or other changes in long-term effectiveness was found in trials, it would be noted in the official results section.

Q: Is Delor used to treat mental health conditions?

A: Official regulatory documents specify the therapeutic indications for which the drug is formally approved. Any use for mental health conditions is not supported by the primary regulatory labeling unless it falls within an approved indication.

Q: Is Delor known by any other name?

A: Yes, official regulatory listings and product labeling define the generic name (International Nonproprietary Name or INN) and all associated brand names under which the product is marketed.

Q: What color are the Delor tablets?

A: The official drug description, found in sections detailing dosage forms and strengths, includes the physical appearance of the tablet, such as its shape, color, and any identifying markings.

Q: Is there a generic version of Delor available?

A: Regulatory databases track whether a generic version of the brand-name product has been granted marketing approval, indicating that therapeutically equivalent products may be available.

Q: Does Delor contain ingredients like gluten or lactose?

A: The official description includes a complete list of excipients (inactive ingredients) used in the drug formulation, which permits the identification of components such as lactose, gluten, or other specific substances.

How should Delor be stored and disposed of?

How to Store and Dispose of Delor: Official Requirements

Official regulatory guidelines strictly define how Delor must be stored and discarded to maintain its quality and ensure safety.

Storage Requirement	Official Classification
Temperature Range	Controlled Room Temperature (20 C to 25 C / 68 F to 77 F)
Handling	Protect from moisture; Do not freeze.
Packaging	Keep in the original, tightly closed, child-resistant container.
Protection	Keep out of the sight and reach of children.

Unused or expired Delor must be disposed of properly. Do not flush Delor unless instructed by a regulatory body. The preferred disposal method is through an authorized Drug Take-Back Program. If a take-back program is unavailable, mix the medication with an unappealing substance, seal it in a bag, and place it in the household trash.

Delor